Epsilogen announces significant expansion of management team with three new senior hires
26.4.2023 09:00:00 EEST | Business Wire | Press release
Epsilogen Ltd, a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer, announced three new senior hires in what is a significant expansion of their management team. Nick Robbins-Cherry joins as Chief Financial Officer, Andrew Calam as Vice President of Clinical Operations and Elizabeth Hardaker as Vice President of Biology.
Nick Robbins-Cherry, CFO, brings over 30 years of experience in fundraising, public markets and private equity, gained through financial and commercial roles in international pharmaceuticals and technology businesses. Most recently, Nick was CFO of Ixaka Ltd, a private cell and gene therapy company. Prior to this, Nick was CFO at Midatech Pharma PLC, a listed pharmaceutical business with operations in the UK and Spain. He successfully steered Midatech through its IPO on AIM, a dual listing on NASDAQ and subsequent fundraises. Nick is a Chartered Accountant and holds an MBA.
Andrew Calam, VP of Clinical Operations, has over 25 years of experience in the life sciences industry, holding both management and executive positions in the contract research organisation (CRO) and biotechnology sectors, leading and supporting pharmaceutical development. Andrew started his career within the bioanalytical space, before turning his focus to project management. He has a track record of leading multinational teams with responsibility for all aspects of clinical trial management from phase I to phase III trials. Prior to joining Epsilogen, Andrew worked as an Executive Director of Clinical Development at Syneos Health where he was responsible for the development, oversight, execution and management of several clinical programs for targeted cancer therapies.
Elizabeth Hardaker, VP of Biology, joins Epsilogen with over 15 years’ experience in the pharmaceutical industry. Most recently, Elizabeth was a Senior Director at AstraZeneca, leading a team supporting preclinical research in Oncology. Previously, Elizabeth worked at Evotec in the inflammation and immunology group, and Novartis in the respiratory group. Throughout her career Elizabeth has been the biology lead on a number of projects across the drug discovery process, ranging from target validation to clinical trials. Elizabeth has a PhD from the National Heart and Lung Institute, Imperial College and a Masters in Biochemistry from Bath University.
Tim Wilson, Chief Executive Officer of Epsilogen, commented:
“We are delighted to have Elizabeth, Andrew and Nick join our leadership team and we are pleased that we have been able to attract such high-calibre people to Epsilogen. They join the Company at an exciting stage of its development with lead asset MOv18 IgE having successfully completed a phase I clinical trial in ovarian cancer patients and progress being made within our IgE-based therapeutic platforms.”
ENDS
About Epsilogen Ltd
Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE’s natural function is to provide immunological defense against certain parasites. This functionality makes it an ideal treatment of solid tumours due to its strong potency, enhanced tumour access and long tissue half-life.
Epsilogen’s lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic and encouraging data from a phase I trial demonstrated MOv18 IgE to be safe and well tolerated with early signs of clinical activity also seen. The company is also developing a proprietary IGEGTM antibody platform combining elements from both IgE and IgG antibodies into novel and proprietary antibody molecules with enhanced functionality.
Epsilogen began operations in 2017 as a spin out of King’s College London and has attracted investment funding from top tier investors including Epidarex Capital, Novartis Venture Fund, British Patient Capital, 3B Future Health Fund, ALSA Ventures and Schroders Capital. Find out more at epsilogen.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230425005971/en/
Contact information
Communications advisor to Epsilogen Ltd:
Simon Conway / Rob Winder
FTI Consulting
epsilogen@fticonsulting.com
+44 (0)20 3727 1000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Filippo Fagnani from Quanta System Receives the EAU Award for Significant Contribution to Endourology at ICE 202610.10.2026 19:09:00 EEST | Press release
Filippo Fagnani, Marketing & Scientific Director of Quanta System’s Surgical Division, has been honoured with the Award for Significant Contribution to Endourology at ICE26, the International Conference on Endourology organised by the EAU Endourology Section. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010101303/en/ Filippo Fagnani receiving the prize with Olivier Traxer and Professor Bhaskar Somani. The recognition celebrates more than two decades of professional commitment to laser technology and a career built around a clear ambition: to translate the needs of urologists into increasingly precise, flexible and useful technologies, with the ultimate goal of supporting patient safety and better surgical outcomes. “I have always believed that technology should make the surgeon’s work more precise, more flexible and, most importantly, safer for the patient. My goal has never been to develop technology for its own sake,
Emdoor Information Marks 18 Years of Rugged Computing Excellence with Vertically Integrated Capabilities10.10.2026 13:30:00 EEST | Press release
As industrial automation, smart manufacturing, and field operations increasingly depend on mission-critical mobile computing, global demand for reliable rugged tablets, rugged laptops, and rugged handhelds continues to accelerate. Emdoor Information, a publicly listed company on China’s A-share main board since 2023 and an 18-year veteran in rugged computing, has established itself as a rugged computing solutions provider for industrial customers worldwide. Founded in 2008, the company delivers sustained growth, world-class manufacturing, resilient supply chains, full-stack R&D, and comprehensive lifecycle services. Its rugged computing products and industrial customers now span North America, Latin America, Europe, and Asia-Pacific, serving sectors such as public utilities, intelligent manufacturing, warehouse management, transportation, energy industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010564561/en/ Rugged
Vertex to Present New Data on ALYFTREK ® at the North American Cystic Fibrosis Conference9.10.2026 20:15:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine pancreatic function represent a profound shift in how we understand the benefits of treating cystic fibrosis in its earliest stages,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Devel
Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 17:00:00 EEST | Press release
Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Stable Outlook from Fitch Ratings, assigned on 12 June 2026. Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation of the company’s
Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 16:17:00 EEST | Press release
Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magic Quadrant confirms the shift has moved from pilot to boardroom priority. According to Gartner, Visionaries "understands where the market
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom